Study guide

2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis

USMLE Step 2 CK Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Human Development & Well-Patient Care

1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening

2 Chapter 2: Immune System & Immunologic Disorders

2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles

3 Chapter 3: Blood & Lymphoreticular System

3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders

4 Chapter 4: Behavioral Health & Psychiatric Disorders

4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology

5 Chapter 5: Nervous System & Special Senses

5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies

6 Chapter 6: Musculoskeletal System & Dermatology

6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders

7 Chapter 7: Cardiovascular System

7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease

8 Chapter 8: Respiratory System

8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases

9 Chapter 9: Gastrointestinal System

9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis

10 Chapter 10: Renal, Urinary & Reproductive Systems

10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease

11 Chapter 11: Pregnancy, Childbirth & Puerperium

11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management

12 Chapter 12: Endocrine System

12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology

13 Chapter 13: Multisystem Processes & Critical Care

13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens

14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation

14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine

15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice

15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions

2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis

Key Takeaways Explain This Topic AI

Anaphylaxis is diagnosed by acute skin/mucosal involvement paired with respiratory compromise or hypotension/end-organ dysfunction, confirmed diagnostically by serum tryptase levels peaking 1–2 hours post-event.

First-line immediate treatment for anaphylaxis is intramuscular epinephrine 0.3–0.5 mg (1:1,000 dilution) into the mid-outer thigh (vastus lateralis), repeatable every 5–15 minutes; adjunctive antihistamines and steroids must never delay epinephrine.

Biphasic anaphylactic reactions occur in up to 20% of cases within 1 to 72 hours (median 8–12 hours) after initial symptom resolution, necessitating a mandatory observation period of 4–8 hours post-stabilization.

Type II hypersensitivity involves antibody-mediated (IgG/IgM) cytotoxic destruction via complement activation or ADCC (e.g., Goodpasture syndrome, autoimmune hemolytic anemia), whereas Type III involves immune complex deposition causing vasculitis and complement consumption (e.g., Serum sickness, SLE nephritis).

Type IV hypersensitivity is cell-mediated by CD4+ and CD8+ T lymphocytes with delayed onset (48–72 hours), evaluated clinically via patch testing for allergic contact dermatitis or PPD/IGRA for tuberculosis.

Last updated: July 2026

  • Hypersensitivity Reactions, Allergy & Anaphylaxis
  • Gell & Coombs Classification of Hypersensitivity

Hypersensitivity reactions are exaggerated or inappropriate immune responses causing tissue destruction or organ dysfunction. Gell and Coombs categorized these reactions into four immunological types based on effector mechanism, immune components involved, and time to onset.

Comparison of Hypersensitivity Types

Type Name Primary Immune Mechanism Key Mediators Clinical Examples Typical Onset

Type I Immediate (Allergic) IgE cross-linking on mast cells/basophils Histamine, leukotrienes (LTC4, LTD4, LTE4), tryptase Anaphylaxis, allergic asthma, food allergy, allergic rhinitis Immediate (Minutes to <1 hour)

Type II Antibody-Mediated (Cytotoxic) IgG or IgM binding to cell surface/tissue antigens Complement activation (C3a, C5a), MAC, ADCC, phagocytosis Goodpasture syndrome, Autoimmune hemolytic anemia, ITP, Rheumatic fever Hours to days

Type III Immune Complex-Mediated Circulating IgG/IgM-antigen complexes depositing in vessel walls Complement consumption (C3/C4), neutrophil recruitment Serum sickness, Systemic Lupus Erythematosus nephritis, Post-streptococcal glomerulonephritis 1 to 3 weeks

Type IV Cell-Mediated (Delayed) Sensitized T cells (CD4+ Th1/Th17, CD8+ CTLs) releasing cytokines IFN-gamma, TNF-alpha, interleukins, macrophage activation Contact dermatitis (poison ivy, nickel), Stevens-Johnson syndrome, Graft-vs-host disease, PPD test 48 to 72 hours

  • Type I Hypersensitivity & Anaphylaxis
  • Pathophysiology

Sensitization occurs upon initial allergen exposure when antigen-presenting cells drive CD4+ T helper 2 (Th2) differentiation. Th2 cells secrete IL-4 and IL-13 , stimulating B-cell class switching to IgE . Specific IgE binds high-affinity FcεRI receptors on tissue mast cells and circulating basophils. Upon re-exposure, multivalent allergen cross-links membrane-bound IgE, inducing immediate degranulation. Preformed mediators ( histamine , tryptase , carboxypeptidase A ) cause rapid vasodilation, increased vascular permeability, smooth muscle contraction, and mucus hypersecretion. Membrane phospholipid metabolism subsequently releases synthesized mediators: leukotrienes (LTC4, LTD4, LTE4) (potent bronchoconstrictors) and prostaglandin D2 .

Clinical Diagnostic Criteria for Anaphylaxis

Anaphylaxis is a life-threatening systemic reaction. Diagnosis is clinical and requires meeting any ONE of the following three scenarios:

Acute onset (minutes to hours) involving skin/mucosal tissue (urticaria, angioedema, flushing, pruritus) PLUS AT LEAST ONE OF :

  • Respiratory compromise (dyspnea, wheezing, stridor, hypoxemia, peak expiratory flow reduction)
  • Reduced blood pressure or associated end-organ dysfunction (syncope, incontinence, hypotonia)

Two or more of the following occurring rapidly after exposure to a likely allergen:

  • Skin-mucosal involvement
  • Respiratory compromise
  • Reduced blood pressure or end-organ dysfunction
  • Persistent gastrointestinal symptoms (crampy abdominal pain, vomiting)

Hypotension after exposure to a known allergen for that patient (systolic BP <90 mmHg or >30% drop from baseline).

Serum tryptase levels peak 1 to 2 hours post-event and confirm mast cell activation if the diagnosis is ambiguous.

Acute Management Protocol for Anaphylaxis

First-line treatment must never be delayed for diagnostic testing. Intramuscular epinephrine is the cornerstone of emergency therapy.

  • Step-by-Step Management Algorithm Patient Presenting with Suspected Anaphylaxis
  • ├─ Step 1: IMMEDIATE INTERVENTION
  • │ ├─ Administer Epinephrine 1:1,000 (1 mg/mL) IM into Anterolateral Thigh
  • │ │ ├─ Adult Dose: 0.3 to 0.5 mg IM
  • │ │ └─ Pediatric Dose: 0.01 mg/kg IM (Max 0.3 mg)
  • │ ├─ Call for emergency assistance / Airway management team
  • │ ├─ Place patient in recumbent position with legs elevated (unless airway compromised)
  • │ └─ Administer supplemental high-flow oxygen via non-rebreather mask
  • │
  • ├─ Step 2: CIRCULATORY & AIRWAY RESUSCITATION
  • │ ├─ Establish dual large-bore IV access (14-16 gauge)
  • │ ├─ Rapid IV normal saline bolus (1–2 Liters for adults; 20 mL/kg for children)
  • │ └─ Prepare for early endotracheal intubation if stridor, airway edema, or voice change occurs
  • │
  • ├─ Step 3: SECOND-LINE ADJUNCTIVE THERAPIES (Do NOT delay Epinephrine!)
  • │ ├─ H1 Antihistamine: IV Diphenhydramine (25–50 mg) for urticaria and pruritus
  • │ ├─ H2 Antihistamine: IV Famotidine (20 mg) for vascular stabilization
  • │ ├─ Inhaled Beta-2 Agonist: Albuterol nebulizer for refractory bronchospasm
  • │ └─ Systemic Corticosteroids: IV Methylprednisolone (1–2 mg/kg) to prevent protracted symptoms
  • │
  • └─ Step 4: POST-STABILIZATION MONITORING
  • ├─ Mandatory observation for 4 to 8 hours due to risk of Biphasic Reaction (occurs in up to 20%)
  • └─ Discharge prescription: Two Epinephrine Auto-Injectors + Written Allergy Action Plan
  • Epinephrine Pharmacology

Epinephrine acts as an agonist across multiple adrenergic receptor subtypes:

Alpha-1 receptor agonist : Causes peripheral vasoconstriction, reversing hypotension, mucosal edema, and urticaria.

Beta-1 receptor agonist : Increases cardiac inotropy and chronotropy.

Beta-2 receptor agonist : Induces bronchodilation and inhibits further mediator release from mast cells and basophils.

  • Type II, III, and IV Hypersensitivity Disorders
  • Type II (Cytotoxic Antibody-Mediated)

Circulating IgG or IgM autoantibodies bind fixed tissue antigens. Mechanisms include:

Complement-mediated lysis and opsonization : Autoimmune hemolytic anemia, transfusion reactions.

Antibody-dependent cellular cytotoxicity (ADCC) : Natural killer cells bind Fc regions of antibodies to destroy target cells.

Antibody-mediated cell dysfunction : Antibodies stimulate or block cell surface receptors without tissue destruction. Examples include Graves disease (activating TSH-receptor antibodies) and Myasthenia gravis (blocking/internalizing ACh-receptor antibodies).

Type III (Immune Complex-Mediated)

Antigen-antibody complexes form in the bloodstream and deposit in microvascular beds (renal glomeruli, synovia, skin capillaries). Deposited complexes activate complement, generating C3a and C5a (anaphylatoxins) that recruit neutrophils. Neutrophils release lysosomal enzymes, causing leukocytoclastic vasculitis and tissue necrosis.

Serum Sickness : Occurs 7 to 14 days after exposure to foreign protein (e.g., chimeric monoclonal antibodies, antivenom). Symptoms include fever, urticaria, polyarthralgias, lymphadenopathy, proteinuria, and low complement levels (C3/C4).

Type IV (Cell-Mediated / Delayed-Type)

Unlike Types I–III, Type IV reactions do not involve antibodies. Sensitized CD4+ Th1 cells release IFN-gamma , activating macrophages, or CD8+ cytotoxic T cells directly kill target cells presenting haptenized peptides.

Allergic Contact Dermatitis : Triggered by haptens such as urushiol (poison ivy/oak), nickel , or topical antibiotics. Presents 48–72 hours post-exposure with erythematous, pruritic vesicles. Diagnosis is evaluated using patch testing .

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) : Life-threatening Type IV drug reaction presenting 2–8 weeks after drug initiation (e.g., allopurinol, antiepileptics), featuring fever, facial edema, diffuse morbilliform exanthem, eosinophilia (>1,500/mm³), and internal organ involvement (hepatitis, nephritis).